Insider Selling: Equillium (NASDAQ:EQ) COO Sells $26,516.70 in Stock

Equillium, Inc. (NASDAQ:EQ) COO Christine Zedelmayer sold 9,821 shares of the company’s stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $2.70, for a total transaction of $26,516.70. Following the transaction, the chief operating officer directly owned 62,586 shares in the company, valued at approximately $168,982.20. This trade represents a 13.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christine Zedelmayer also recently made the following trade(s):

• On Thursday, May 28th, Christine Zedelmayer sold 86,012 shares of Equillium stock. The stock was sold at an average price of $2.80, for a total transaction of $240,833.60.
• On Friday, March 13th, Christine Zedelmayer sold 120,312 shares of Equillium stock. The stock was sold at an average price of $2.50, for a total transaction of $300,780.00.
• On Monday, March 9th, Christine Zedelmayer sold 181,219 shares of Equillium stock. The stock was sold at an average price of $2.00, for a total transaction of $362,438.00.

Equillium Price Performance

NASDAQ:EQ opened at $2.90 on Monday. Equillium, Inc. has a fifty-two week low of $0.27 and a fifty-two week high of $3.10. The stock has a market cap of $183.37 million, a PE ratio of -9.06 and a beta of 1.77. The firm’s fifty day simple moving average is $2.11 and its 200-day simple moving average is $1.64.

Equillium (NASDAQ:EQ) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). Equities analysts anticipate that Equillium, Inc. will post -0.24 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on EQ shares. Stifel Nicolaus set a $5.00 price objective on shares of Equillium in a research note on Thursday. B. Riley Financial started coverage on shares of Equillium in a research note on Thursday, April 16th. They issued a “buy” rating and a $6.00 price objective on the stock. Wall Street Zen cut shares of Equillium from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Roth Mkm reissued a “buy” rating and issued a $12.00 price objective on shares of Equillium in a research note on Thursday. Finally, Leerink Partners raised shares of Equillium from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $1.00 to $6.00 in a research note on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $7.57.

Equillium News Roundup

Here are the key news stories impacting Equillium this week:

• Positive Sentiment: Leerink Partners upgraded Equillium from market perform to outperform and lifted its price target to $6.00, suggesting meaningful upside from current levels. Leerink Upgrades Equillium (EQ) to Outperform
• Positive Sentiment: Roth Mkm reiterated a buy rating and set a $12.00 target, reinforcing a bullish view on Equillium’s pipeline and valuation. Equillium Receives Buy Rating from Roth Mkm
• Positive Sentiment: Equillium announced it will participate in the 2026 Jefferies Global Healthcare Conference, which could provide a catalyst if management shares favorable clinical or strategic updates. Equillium to Participate in the 2026 Jefferies Global Healthcare Conference
• Positive Sentiment: Shareholders approved a reverse split and capital changes at the annual meeting, a step that can help maintain Nasdaq compliance and potentially improve the company’s capital structure. Equillium Shareholders Approve Reverse Split and Capital Changes
• Neutral Sentiment: Short interest was reported at 0 shares, indicating no meaningful bearish positioning in the latest update, though the figure appears unusual and may not be a reliable market signal. Short interest update
• Negative Sentiment: COO Christine Zedelmayer sold a combined 95,833 shares over two transactions, and insider Penny Tom sold 65,000 shares; although both were made under pre-arranged 10b5-1 plans, insider selling can still pressure sentiment. SEC Form 4 insider sales filing

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP purchased a new position in Equillium in the 1st quarter valued at about $31,000. Virtu Financial LLC lifted its holdings in Equillium by 133.4% in the 3rd quarter. Virtu Financial LLC now owns 23,779 shares of the company’s stock valued at $34,000 after purchasing an additional 13,591 shares in the last quarter. Millennium Management LLC purchased a new position in Equillium in the 3rd quarter valued at about $35,000. Persistent Asset Partners Ltd purchased a new position in Equillium in the 3rd quarter valued at about $99,000. Finally, OMERS ADMINISTRATION Corp purchased a new position in Equillium in the 1st quarter valued at about $100,000. 27.05% of the stock is currently owned by hedge funds and other institutional investors.

About Equillium

Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies.